1086064-46-1 Usage
General Description
6-bromo-1-methyl-1H-pyrrolo[3,2-b]pyridine is a chemical compound with the molecular formula C8H7BrN2. It is a brominated derivative of the pyrrolopyridine family and is commonly used in organic synthesis and medicinal chemistry. 6-broMo-1-Methyl-1H-pyrrolo[3,2-b]pyridine6-broMo-1-Methyl-1H-pyrrolo[3,2-b]pyridine has a pyrrole ring fused to a pyridine ring, with a methyl and a bromine substituent at the 1 and 6 positions, respectively. 6-broMo-1-Methyl-1H-pyrrolo[3,2-b]pyridine6-broMo-1-Methyl-1H-pyrrolo[3,2-b]pyridine finds applications as a building block in the synthesis of various biologically active molecules and pharmaceuticals. It is important to handle this compound with proper safety precautions, as brominated compounds can be hazardous if not handled properly.
Check Digit Verification of cas no
The CAS Registry Mumber 1086064-46-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,8,6,0,6 and 4 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1086064-46:
(9*1)+(8*0)+(7*8)+(6*6)+(5*0)+(4*6)+(3*4)+(2*4)+(1*6)=151
151 % 10 = 1
So 1086064-46-1 is a valid CAS Registry Number.
1086064-46-1Relevant articles and documents
TRICYCLIC DLK INHIBITORS AND USES THEREOF
-
, (2016/09/26)
The invention relates to compounds of formula (I) and salts thereof, wherein ring A and R1-R2 have any of the values defined in the specification. The compounds and salts are useful for treating DLK mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as methods of using said compounds, salts, or compositions as DLK inhibitors and for treating neurodegeneration diseases and disorders.
DERIVATIVES OF 2-[2-(BENZO- OR PYRIDO-) THIAZOLYLAMINO]-6-AMINOPYRIDINE, USEFUL IN THE TREATMENT OF RESPIRATORIC, ALLERGIC OR INFLAMMATORY DISEASES
-
Page/Page column 66, (2011/10/05)
The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular Itk activity.
